Please use this identifier to cite or link to this item: https://doi.org/10.1038/tpj.2010.12
DC FieldValue
dc.titleBDNF Val66Met genotype and 6-month remission rates in late-life depression
dc.contributor.authorTaylor, W.D.
dc.contributor.authorMcQuoid, D.R.
dc.contributor.authorAshley-Koch, A.
dc.contributor.authorMacFall, J.R.
dc.contributor.authorBridgers, J.
dc.contributor.authorKrishnan, R.R.
dc.contributor.authorSteffens, D.C.
dc.date.accessioned2014-11-26T09:03:40Z
dc.date.available2014-11-26T09:03:40Z
dc.date.issued2011-04
dc.identifier.citationTaylor, W.D., McQuoid, D.R., Ashley-Koch, A., MacFall, J.R., Bridgers, J., Krishnan, R.R., Steffens, D.C. (2011-04). BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics Journal 11 (2) : 146-154. ScholarBank@NUS Repository. https://doi.org/10.1038/tpj.2010.12
dc.identifier.issn1470269X
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/110494
dc.description.abstractAlthough not observed in younger adult cohorts, in older individuals the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with major depressive disorder (MDD) risk. It is further associated with subjective social support and magnetic resonance imaging (MRI) hyperintense lesions, clinical features independently related to MDD. We examined the relationship between this polymorphism and antidepressant remission rates in an elderly sample with MDD, while also testing for mediation effects of social support and hyperintensities. A total of 229 elderly Caucasian subjects with MDD completed baseline assessments, 1.5 T MRI, and BDNF genotyping. They received antidepressant medication under a structured treatment algorithm and were evaluated for remission at 3 and 6 months. At the 3-month evaluation, BDNF Val66Met genotype was not associated with remission (Wald's X2 = 2.51, P=0.1131). When not controlling for multiple comparisons, Met66 allele carriers were more likely to be remitted at 6 months ( X2 = 4.32, P=0.0377) with an odds ratio of 1.82 (95% CI: 1.04, 3.22). This effect persisted after controlling for lesion volume and social support, neither of which mediated this relationship. Thus in this exploratory analysis, the Met66 allele may be associated with increased odds of remission in older subjects, but also with increased time to remission as there was no 3-month effect. © 2011 Macmillan Publishers Limited. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/tpj.2010.12
dc.sourceScopus
dc.subjectantidepressant response
dc.subjectBDNF
dc.subjectgenetic polymorphism
dc.subjectgeriatrics
dc.subjectmajor depressive disorder
dc.typeArticle
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.description.doi10.1038/tpj.2010.12
dc.description.sourcetitlePharmacogenomics Journal
dc.description.volume11
dc.description.issue2
dc.description.page146-154
dc.description.codenPJHOA
dc.identifier.isiut000288849900009
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

38
checked on Nov 27, 2020

WEB OF SCIENCETM
Citations

36
checked on Nov 27, 2020

Page view(s)

75
checked on Nov 28, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.